Geron Corporation

Equities

GERN

US3741631036

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:16:37 2024-04-19 pm EDT			5-day change	1st Jan Change
3.795 ^USD	+1.74%		+4.40%	+80.09%

Mar. 19	Geron Prices $150 Million Offering of Shares, Pre-Funded Warrants	MT
Mar. 15	Sector Update: Health Care Stocks Ease Late Afternoon	MT

Geron Announces November Investor Conference Presentation Webcasts

November 07, 2016 at 07:31 am EST

MENLO PARK, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the following investor conferences:

Stifel 2016 Healthcare Conference in New York at 9:30 a.m. ET on Tuesday, November 15, 2016.
Piper Jaffray 28^th Annual Healthcare Conference in New York at 12:30 p.m. ET on Wednesday, November 30, 2016.

A live audio webcast of each presentation will be available through the Homepage and Investor Relations section of Geron’s website under Events. Following the live presentations, the webcasts will be archived and available for replay for a period of 30 days.

About Geron

Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

CONTACT:

Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
investor@geron.com
media@geron.com

Primary Logo

Latest news about Geron Corporation

Geron Prices $150 Million Offering of Shares, Pre-Funded Warrants	Mar. 19	MT
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 15	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	Mar. 15	MT
Sector Update: Health Care	Mar. 15	MT
Needham Adjusts Geron's Price Target to $5 From $4, Maintains Buy Rating	Mar. 15	MT
Top Midday Gainers	Mar. 15	MT
Geron Shares Soar on Positive FDA Advisory Panel's Vote on Imetelstat for Blood Disorder	Mar. 15	MT
Goldman Sachs Adjusts Price Target on Geron to $5 From $4, Keeps Buy Rating	Mar. 15	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	Mar. 15	MT
Sector Update: Health Care	Mar. 15	MT
Investors Turn Cautious Ahead of Next Week's Fed Meeting, Stifling US Equity Futures Pre-Bell	Mar. 15	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday as Rate Cut Hopes Wane	Mar. 15	MT
Top Premarket Gainers	Mar. 15	MT
Geron Gets Favorable Vote From FDA Advisory Committee on Imetelstat for Blood Disorder	Mar. 14	MT
Geron Corporation Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS	Mar. 14	CI
Geron's blood disorder drug gets FDA advisers' backing	Mar. 14	RE
Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 12	MT
Sector Update: Health Care	Mar. 12	MT
Geron's Imetelstat's Safety a Key Focus for FDA's Oncology Drugs Advisory Committee Meeting; Shares Slump	Mar. 12	MT
Geron's Imetelstat's Safety a Key Focus for FDA's Oncology Drugs Advisory Committee Meeting	Mar. 12	MT
US FDA staff flags concerns about Geron's anemia treatment	Mar. 12	RE
Geron's Q4 Net Loss Narrows, Revenue Declines	Feb. 28	MT
Transcript : Geron Corporation, Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Geron Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Geron Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI

Chart Geron Corporation

Duration

Period

More charts

Company Profile

Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Geron Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.73 USD

Average target price

5.083 USD

Spread / Average Target

+36.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GERON CORPORATION	+80.09%	2.2B
VERTEX PHARMACEUTICALS INCORPORATED	-2.80%	102B
REGENERON PHARMACEUTICALS, INC.	+1.83%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.67%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-27.98%	13.79B
NEUROCRINE BIOSCIENCES, INC.	-0.20%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.30%	10.94B

Bio Therapeutic Drugs